Table 2.
Clinical and laboratory characteristics according to the monocyte-to-HDL ratio quartiles
| Parameters | Q1(≤0.19) N = 167 |
Q2(0.19–0.33) N = 177 |
Q3(0.33–0.53) N = 158 |
Q4(> 0.53) N = 171 |
P |
|---|---|---|---|---|---|
| Age(years) | 57 ± 11 | 58 ± 11 | 60 ± 11 | 59 ± 11 | 0.045 |
| Male sex [n (%)] | 120(71.9%) | 144(81.8%) | 130(82.3%) | 149(87.3%) | 0.004 |
| Smoking [n (%)] | 69(41.3%) | 84(47.5%) | 82(51.9%) | 80(46.8%) | 0.297 |
| Alcohol intake [n (%)] | 54(32.3%) | 62(35.0%) | 69(43.7%) | 66(38.6%) | 0.171 |
| Hypertension [n (%)] | 74(44.3%) | 82(46.3%) | 80(50.6%) | 87(50.9%) | 0.551 |
| Family history of CAD [n (%)] | 34(20.4%) | 38(21.5%) | 34(21.5%) | 39(22.8%) | 0.960 |
| Hypercholesterolemia[n (%)] | 65(38.9%) | 70(39.5%) | 76(48.1%) | 76(44.4%) | 0.286 |
| Diabetes [n (%)] | 41(24.6%) | 44(24.9%) | 40(25.3%) | 45(26.3%) | 0.984 |
| LVEF (%) | 61 ± 7 | 62 ± 7 | 61 ± 7 | 61 ± 8 | 0.401 |
| Gensini score | 43 ± 43 | 45 ± 42 | 46 ± 37 | 52 ± 35 | 0.150 |
| Laboratory parameters | |||||
| SBP (mmHg) | 130 ± 21 | 131 ± 24 | 135 ± 29 | 139 ± 29 | 0.003 |
| HR (bpm) | 73 ± 9 | 74 ± 10 | 75 ± 11 | 76 ± 10 | 0.068 |
| WBC(×109/l) | 6.73 ± 2.14 | 7.36 ± 1.88 | 7.58 ± 2.43 | 8.28 ± 2.58 | < 0.001 |
| MO(×109/l) | 0.36 ± 0.05 | 0.51 ± 0.18 | 0.54 ± 0.22 | 0.67 ± 0.23 | < 0.001 |
| HB(× 1012/l) | 141 ± 14 | 140 ± 16 | 139 ± 15 | 139 ± 14 | 0.499 |
| RDW(%) | 13.21 ± 0.98 | 13.17 ± 0.79 | 13.15 ± 0.81 | 13.24 ± 0.20 | 0.778 |
| PLT(×109/l) | 212 ± 59 | 217 ± 72 | 211 ± 61 | 212 ± 61 | 0.847 |
| BUN(mmol/l) | 5.49 ± 1.41 | 5.53 ± 1.63 | 5.40 ± 1.66 | 5.40 ± 1.70 | 0.823 |
| FBG(mmol/l) | 6.15 ± 2.55 | 6.27 ± 2.51 | 6.54 ± 3.03 | 6.93 ± 2.91 | 0.045 |
| TG(mmol/l) | 2.12 ± 1.25 | 1.87 ± 1.23 | 1.87 ± 1.15 | 2.37 ± 1.70 | 0.001 |
| TC(mmol/l) | 4.53 ± 1.06 | 3.97 ± 1.09 | 3.93 ± 1.46 | 3.73 ± 1.07 | < 0.001 |
| HDL-C(mmol/l) | 2.89 ± 0.95 | 2.05 ± 0.78 | 1.31 ± 0.51 | 0.86 ± 0.30 | < 0.001 |
| LDL-C(mmol/l) | 1.27 ± 0.50 | 1.51 ± 0.98 | 1.97 ± 1.10 | 2.14 ± 0.97 | < 0.001 |
| MHR | 0.12 ± 0.05 | 0.25 ± 0.04 | 0.42 ± 0.06 | 0.82 ± 0.31 | < 0.001 |
| IBIl(umol/l) | 8.57 ± 4.43 | 9.21 ± 5.52 | 8.89 ± 5.22 | 8.26 ± 4.56 | 0.318 |
| DBIL(umol/l) | 3.17 ± 2.02 | 3.51 ± 2.28 | 3.45 ± 2.59 | 3.10 ± 2.34 | 0.270 |
| Drugs parameters | |||||
| Regular drugs taking | 142(85%) | 153(86.4%) | 143(90.5%) | 156(91.2%) | 0.215 |
| Clinical result | |||||
| Follow up time(m) | 45 ± 26 | 45 ± 29 | 37 ± 25 | 31 ± 16 | < 0.001 |
| ACM [n (%)] | 1(0.6%) | 1(0.6%) | 4(2.5%) | 8(4.7%) | 0.022 |
| MACE [n (%)] | 15(9%) | 26(14.7%) | 28(17.7%) | 33(19.3%) | 0.044 |
Mo Monocyte, PLT Platelet, BUN Blood urea nitrogen, HB Hemoglobin B, FBG Fasting blood glucose, RDW Red cell distribution width, IBil Indirect bilirubin, DBIL Direct bilirubin, ACM All-cause mortality, MACE Major adverse cardiac events